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Abstract	
Birth weight is an important indicator of maternal and fetal health and a predictor of health in later 
life. However, the determinants of variance in birth weight are still poorly understood. We aimed to 
identify the biological pathways, which may be perturbed by environmental exposures, that are 
important in determining birth weight. We applied untargeted mass-spectrometry-based 
metabolomics to 481 cord blood samples collected at delivery in four birth cohorts from across 
Europe: ENVIRONAGE (Belgium), INMA (Spain), Piccolipiu (Italy), and Rhea (Greece). We 
performed a metabolome-wide association scan for birth weight on over 4000 metabolic features, 
controlling the false discovery rate at 5%. Annotation of compounds was conducted through 
reference to authentic standards. We identified 68 metabolites significantly associated with birth 
weight, including vitamin A, progesterone, docosahexaenoic acid, indolelactic acid, and multiple 
acylcarnitines and phosphatidylcholines. We observed enrichment (p < 0.05) of the tryptophan 
metabolism, prostaglandin formation, C21-steroid hormone signaling, carnitine shuttle, and 
glycerophospholipid metabolism pathways. Vitamin A was associated with both maternal smoking 
and birth weight, suggesting a mediation pathway. Our findings shed new light on the pathways 
central to fetal growth and will have implications for antenatal and perinatal care and potentially for 
































































































































































   N (%) or mean (IQR) missing values mean birth weight (IQR) or r with birth weight p valuea
birth weight (g)  3309 (2992–3598) 1 – –
gestational age (weeks)  39.2 (38.1–40) 1 0.21 <0.0001
cohort     0 0.014
Rhea  100 (20) – 3220 (2970–3520) 
Environage  200 (40) – 3384 (3045–3705) 
Piccolipiu  99 (20) – 3221 (2955–3490) 
Inma  100 (20) – 3298 (2998–3572) 
sex     1 0.0005
male  258 (52) – 3377 (3076–3648) 
female  240 (48) – 3237 (2915–3550) 
parity     4 0.13
0  129 (26) – 3275 (2990–3570) 
1  238 (48) – 3294 (2971–3579) 
2  128 (260) – 3379 (3119–3640) 
season of conception     3 0.35
January–March  122 (25) – 3318 (3000–3550) 
April–June  129 (26) – 3296 (2970–3600) 
July–September  160 (32) – 3348 (3019–3630) 
   N (%) or mean (IQR) missing values mean birth weight (IQR) or r with birth weight p valuea
October–December  85 (17) – 3240 (2980–3485) 
delivery     2 0.18
vaginal  382 (77) – 3324 (3000–3614) 
caesarean  115 (23) – 3259 (2960–3542) 
maternal age (y)  30.7 (27.9–34) –0.04 0.44
maternal height (cm)  164.5 (160–168) 2 0.27 <0.0001
maternal weight (kg)  62 (42–130) 2 0.24 <0.0001
maternal BMI  23 (20.8–25.8) 2 0.15 0.001
maternal weight gain (kg)  13.63 (10–17) 13 0.21 0.0002
paternal height (cm)  177.8 (173–182) 17 0.14 0.003
paternal weight (kg)  82 (73–90) 17 0.07 0.11
mother born in country     9 0.69
yes  432 (88) – 3315 (3000–3586) 
no  58 (12) – 3287 (2881–3638) 
mother’s education     12 0.64
primary school  62 (13) – 3291 (2975–3595) 
secondary school  209 (43) – 3296 (2980–3590) 
university or higher  216 (44) – 3333 (3060–3589) 
father’s education     28 0.08
primary school  96 (20) – 3236 (2915–3550) 
secondary school  227 (47) – 3288 (2982–3580) 
university or higher  148 (30) – 3365 (3084–3600) 
maternal smoking (during second trimester)     3 0.06
yes  57 (11%) – 3207 (2890–3440) 
no  439 (89%) – 3324 (3000–3612) 
passive smoke exposure     15 0.50
yes  172 (36) – 3295 (2970–3616) 
no  312 (64) – 3324 (3000–3592) 
   N (%) or mean (IQR) missing values mean birth weight (IQR) or r with birth weight p valuea
exposure to PM10 (μg/m3)  33.0 (17.8–44.0) 4 –0.13 0.002
exposure to PM2.5 (μg/m3)  18.14 (12.4–21.0) 4 –0.11 0.02
exposure to NO2 (μg/m3)  29.1 (13.4–40.3) 4 –0.11 0.02
a 
p value for association with birth weight, calculated from Pearson’s correlation test (continuous 














After grouping of ions originating from the same molecule (matched by retention time and pairwise 
feature correlation), there were 68 unique compounds associated with birth weight. Twenty-nine of 
these were annotated to at least the level of compound class based on matching mass, isotope 
pattern, and product ion spectra (Table 2). Fifteen compounds were identified as acylcarnitines, nine 
as phosphatidylcholines (PCs) or lysoPCs, two as tryptophan metabolites (indolelactic acid and an 
isomeric form of methoxykynurenate), two as essential nutrients (retinol (vitamin A) and 
docosahexaenoic acid (DHA)), and one as a steroid hormone. Seven of these were conclusively 
identified through comparisons with authentic standards: decanoylcarnitine, dodecanoylcarnitine 
and tetradecanoylcarnitine, indolelactic acid, retinol, the ω-3 fatty acid DHA, and progesterone, one 
of the major progestational steroid hormones. In addition to the 29 annotated metabolites, five 
compounds (three diacylglycerols and two lysoPCs) were tentatively assigned based on exact mass 
and isotope pattern due to low intensity or lack of MS/MS spectra or authentic standards (Table 2). 
Retention time and exact mass of all significantly associated features, including unassigned 
compounds, is given in Table s1. Chromatograms and mass spectra of all annotated compounds are 
given in the Supporting Information in Additional Data Set 1. 
 
Table 2. Metabolites Significantly Associated with Birth Weight 
m/z retention 
time (min) 
ion namea ID levelb compound class direction of change with 
increasing birth weight 
P value 
368.2793 5.631 [M+H]+ 3,5-tetradecadiencarnitine (C14:2) 2 acylcarnitine DOWN 1.00 × 10–
8 




ion namea ID levelb compound class direction of change with 
increasing birth weight 
P value 
494.3250 6.817 [M+H]+ LysoPC (C16:1) 2 glycerophospholipid UP 7.45 × 10–
8 
344.2797 5.647 [M+H]+ dodecanoylcarnitine (C12:0) 1 acylcarnitine DOWN 8.31 × 10–
8 
206.0822 3.829 [M+H]+ indolelactic acid 1 tryptophan 
metabolite 
DOWN 9.16 × 10–
8 
522.3555 6.980 [M+H]+ LysoPC (C18:1) 2 glycerophospholipid UP 1.45 × 10–
7 




retinol 1 vitamin UP 1.30 × 10–
6 
639.4946 9.408 [M+Na]+ diacylglycerol (C36:4) 4 glycerolipid DOWN 1.74 × 10–
6 
396.3100 5.944 [M+H]+ 9,12-hexadecadienoylcarnitine (C14:1) 2 acylcarnitine DOWN 2.32 × 10–
6 
522.3565 7.058 [M+H]+ LysoPC (C18:1) 2 glycerophospholipid UP 4.55 × 10–
6 
329.2482 7.232 [M+H]+ docosahexaenoic acid 1 fatty acid DOWN 1.18 × 10–
5 
766.5815 8.859 [M+H]+ PC-O (C36:4) (C44H80NO7P) 3 glycerophospholipid DOWN 1.20 × 10–
5 
316.2489 5.139 [M+H]+ decanoylcarnitine (C10:0) 1 acylcarnitine DOWN 1.30 × 10–
5 
810.6053 9.169 [M+H]+ PC (C38:4) 3 glycerophospholipid DOWN 1.37 × 10–
5 
258.1699 2.831 [M+H]+ 2-hexenoylcarnitine (C6:1) 2 acylcarnitine DOWN 4.43 × 10–
5 
342.2641 5.422 [M+H]+ trans-2-dodecenoylcarnitine (C12:1) 2 acylcarnitine DOWN 4.89 × 10–
5 
314.2318 4.967 [M+H]+ decenoylcarnitine_2 (C10:1)c 2 acylcarnitine DOWN 5.20 × 10–
5 
370.2955 5.840 [M+H]+ tetradecenoylcarnitine (C14:1) 2 acylcarnitine DOWN 5.49 × 10–
5 
615.4959 9.763 [M+Na]+ diacylglycerol (C34:2) 4 glycerolipid DOWN 6.82 × 10–
5 
734.5700 8.960 [M+H]+ PC (C32:0) 3 glycerophospholipid DOWN 1.17 × 10–
4 
314.2321 4.878 [M+H]+ decenoylcarnitine_1 (C10:1)c 2 acylcarnitine DOWN 1.55 × 10–
4 
315.2320 6.394 [M+H]+ progesterone 1 steroid hormone DOWN 2.11 × 10–
4 
288.2171 4.422 [M+H]+ l-octanoylcarnitine (C8:0) 2 acylcarnitine DOWN 3.21 × 10–
4 
232.1537 1.927 [M+H]+ butyrylcarnitine/isobutyryl-l-carnitine 
(C4:0) 
2 acylcarnitine DOWN 3.61 × 10–
4 
220.0605 3.671 [M+H]+ methoxykynurenate (C11H9NO4)d 3 tryptophan 
metabolite 
DOWN 4.69 × 10–
4 
548.3681 7.141 [M+H]+ LysoPC (C20:2) 4 glycerophospholipid UP 5.58 × 10–
4 
782.5712 8.628 [M+H]+ PC (C36:4) 3 glycerophospholipid DOWN 6.03 × 10–
4 
372.3112 6.006 [M+H]+ tetradecanoylcarnitine (C14:0) 1 acylcarnitine DOWN 6.46 × 10–
4 
758.5747 8.684 [M+H]+ PC (C34:2) 3 glycerophospholipid DOWN 7.88 × 10–
4 
570.3551 7.021 [M+H]+ LysoPC (C22:5) 4 glycerophospholipid UP 8.01 × 10–
4 
386.2899 5.568 [M+H]+ 3-hydroxy-cis-5-tetradecenoylcarnitine 
(C14:1) 
2 acylcarnitine DOWN 8.10 × 10–
4 
412.3045 5.750 [M+H]+ 3-hydroxyhexadecadienoylcarnitine 
(C16:1) 
2 acylcarnitine DOWN 9.82 × 10–
4 
398.3264 6.109 [M+H]+ hexadecenoylcarnitine (C16:1) 2 acylcarnitine DOWN 1.01 × 10–
3 
Common names as used in HMDB. Molecular formulas given when identification inconclusive or 
more than one isomers are possible. Chain lengths and number of double bonds are indicated for 
acylcarnitines, glycerophospholipid, and diacylglycerols. 
Level 1 (identified compounds): retention time and MS/MS spectra matches with an authentic 
chemical standard; Level 2 (putatively annotated compound): no standard available or analyzed but 
has a single database candidate within 5 ppm mass error, matching isotope pattern, and MS/MS 
spectra; Level 3 (putatively characterized compound class): MS/MS spectral similarity with 
compounds from a known chemical class; Level 4 (unknown compounds): no standard or MS/MS 
spectra available but a chemically plausible hit in a metabolite database within 5 ppm mass error 
and a matching isotope pattern.(60) 
Two isomers of decenoylcarnitine were identified. 
Likely a positional isomer of methoxykynurenate based on closeness of retention time and 
similarities in spectra to those acquired from authentic standard of 8-methoxykynurenate. 
As shown in clustered correlation heatmap (Figure 2), the longer chained acylcarnitines clustered 
together and were moderately correlated with progesterone, the tryptophan metabolites, and the 
shorter chained acylcarnitines. The PCs, smaller-sized lysoPCs, and tentatively assigned 
diacylglycerols formed three further clusters. The diacylglycerol cluster was moderately correlated 
with DHA. Both the diacylglycerol cluster and DHA were negatively correlated with the cluster of 









To further assess the potential cohort-specific results, we also ran our models on each cohort 
separately (Table s2). Additionally, we stratified by sex and reran analyses after excluding preterm 
and caesarean deliveries (Table s2). Results were generally consistent across cohorts, although we 
noted stronger associations for the smaller sized lysoPCs in the INMA cohort and nonsignificant 
and opposite directions of association for some acylcarnitines (dodecanoylcarnitine, 
decanoylcarnitine, trans-2-dodecenoylcarnitine, and tetradecenoylcarnitine) in Rhea and for the 
three tentatively assigned diacylglycerols in Piccolipiu. These differences largely reflect the 
heterogeneity of the metabolic profiles we observed in each cohort (Figure 3). Upon stratification 
by sex, we observed stronger associations for decanoylcarnitine, tetradecanoylcarnitine, and 
hexadecenoylcarnitine in girls and a stronger association with PC (C40H80NO8P) in boys. 
Associations were similar when preterm and caesarean deliveries were excluded, except for slightly 
stronger associations with decanoylcarnitine and dodecanoylcarnitine in the analysis of vaginal 
deliveries only. 
To test for the potential confounding of our results we additionally adjusted the main model 
separately by factors that influence birth weight. Additional factors included exposure to PM10, 
paternal education, smoking continuing into the second trimester, and maternal weight gain. We 
also checked for the confounding effects of mode of delivery and cohort differences in the 
metabolome data, using the second component of the whole metabolome PCA. As shown in Table 
s3, associations were robust to adjustment by these factors, indicating negligible confounding. 
To investigate the role of the metabolome in potentially mediating the effect of risk factors on birth 
weight, we adjusted a risk factor model of birth weight (including exposure to PM10, maternal and 
paternal education, smoking continuing into the second trimester, and maternal weight gain) by the 
first five principal components of birth-weight-associated metabolites (explaining 50.2% of the total 
variance in the set of 68 metabolites). Of the included risk factors, only the effect size estimate 
linking birth weight and smoking continuing into the second trimester was decreased upon 
adjustment on birth-weight-related metabolites (Table 3). Specifically, while the unadjusted model 
estimated that babies of mothers who smoked during the second trimester weighed 88.5 g (95% 
confidence interval (CI): −197.6 g, 20.5 g) less at birth than babies of mothers who did not, that 
weight loss dropped to 74.0 g (95% CI: −170.7 g, 22.6 g) in the model adjusting for birth-weight-
related metabolites. 
Table 3. Associations of Risk Factors with Birth Weight, with and without Adjustment for 
Metabolites 
  risk factor modela risk factor model, adjusted for birth-weight-
associated metabolomeb 
risk factor model, adjusted for retinol 
levels in cord bloodc 
  β (95% CI) β (95% CI) β (95% CI) 
exposure to PM10 during 
pregnancy 
–3.37 (−11.74, 5.00) –4.97 (−12.40, 2.45) –2.90 (−11.09, 5.28) 
education level of father (ref 
primary school) 
      
secondary school 59.7 (−29.56, 148.96) 80.83 (2.11, 159.54) 71.77 (−15.65, 159.19) 
university or higher 116.08 (16.18, 215.98) 126.04 (38.11, 213.97) 119.19 (21.52, 216.86) 
mother smoked during 
second trimester 
–
88.54 (−197.62, 20.54) 
–74.02 (−170.69, 22.65) –45.06 (−153.30, 63.18) 
maternal weight gain 12.42 (5.77, 19.07) 13.87 (8.00, 19.75) 11.69 (5.18, 18.19) 
Adjusted for gestational age, cohort, maternal height and prepregnancy weight, sex of baby, and 
paternal height. 
Adjusted for gestational age, cohort, maternal height and prepregnancy weight, sex of baby, and 
paternal height and first five principal components of PCA on all birth-weight-associated 
metabolites. 
Adjusted for gestational age, cohort, maternal height and prepregnancy weight, sex of baby, and 
paternal height and levels of retinol in cord blood. 
Linear models investigating the association between the birth-weight-associated metabolites and 
maternal smoking, adjusted for cohort, maternal education, and body mass index, showed that only 
blood retinol levels were significantly different (lower, p = 4.26 × 10–4) among mothers who 
smoked during the second trimester (Figure 4). On the basis of this observation, we additionally 
looked at the evolution of association between birth weight risk factors in a model adjusting for 
retinol levels (Table 3). The effect size estimate of smoking on birth weight was halved upon 
adjustment of retinol levels (β = −45.1 g, 95% CI: −153.3 g, 63.2 g). Although these changes are 




Mummichog software assigned tentative annotations to 1629 of the 4714 features analyzed and 
assigned tentative annotations to 30 of the 138 features associated with birth weight (Supporting 
Information, Additional Data Set 2). Figure 5 shows significantly enriched pathways (p < 0.05) 
identified using Mummichog. We observed the enrichment of eight different pathways; two of these 
involve the synthesis and metabolism of signaling molecules, prostaglandins, and steroid hormones, 
known to be involved in embryogenesis and child birth. 
 Discussion	
 
This is the largest study to date investigating untargeted metabolic profiles of cord blood associated with 
birth‐related outcomes, including weight at birth. Variance in birth weight, a trait that reflects the in 
uterine conditions throughout pregnancy and is an important predictor of health later in life, is determined 
by a complex combination of factors. Twin studies demonstrated the majority of these factors are of 
environmental origin.(32) Here we have shown a metabolic signature associated with birth weight, after 
controlling for hereditary factors such as parental size, among healthy deliveries from the general European 
population. We observed changes in levels of vitamin A, progesterone, and molecules involved in pathways 
related to tryptophan metabolism, carnitine shuttle, fatty acid, and glycerophospholipid metabolism. 
Levels of vitamin A were higher with higher birth weight, confirming findings from previous studies.(33‐36) 
Vitamin A likely promotes fetal growth through its role in cell proliferation and embryogenesis and 
interaction with nuclear receptors to alter gene expression.(37) While our results are consistent with 
changes in cord blood levels of vitamin A associated with smoking previously reported,(38) this is the first 
study to the best of our knowledge that has demonstrated a link between vitamin A and both smoking and 
birth weight in the same population. Cigarette smoke has been shown to induce vitamin A depletion in 
animal models and has been proposed to result from the induction of the CYP1A1 and CYP1A2 enzymes 
and the subsequent increase in catabolism of retinoic acid.(39) Vitamin A depletion, therefore, may present 
an important etiological pathway linking smoking with lower birth weight, which should be further 
investigated. 
Progesterone levels were down‐regulated with increasing birth weight. This corroborates findings from a 
recent targeted study of hormone levels in cord blood among Chinese and American births.(40) 
Progesterone is the major progestational hormone involved throughout all stages of pregnancy. It is 
required for implantation, maintaining intrauterine conditions, and initiating the signaling cascade to 
induce labor. Evidence of the relationship of progesterone measured earlier in pregnancy and birth weight 
is inconsistent.(41‐43) However, levels of progesterone in cord blood appear unrelated to levels measured 
in maternal plasma earlier in pregnancy.(44) This reflects the transition in endocrine metabolism during 
fetal development, with the fetal endocrine system being well developed by late pregnancy. Pregnenolone, 
the precursor in the production of progesterone by the placenta, is transported to the fetus for metabolism 
of large quantities of C‐19 steroid hormones by the fetal adrenal glands, which, in turn, signal back to 
regulate hormonal production by the maternal and placental systems.(45) The size of the fetus may 
influence the production of molecules such as progesterone around the time of labor onset, for instance, to 
increase muscle contractibility during delivery. Furthermore, increased activity of the fetal endocrine 
system in larger babies may reduce the availability of pregnenolone for progesterone production. 
We observed a negative association with birth weight and methoxykynurenate and indolelactic acid. These 
metabolites, never previously associated with birth weight, are both final products of tryptophan 
metabolism, albeit through different routes, the kynurenine and indole pathways. Tryptophan itself was 
identified among the annotated features, and although there was no statistically significant association 
between the amino acid and birth weight (p = 0.07), our results indicate altered utilization of tryptophan. 
Progesterone has been demonstrated to regulate tryptophan metabolism through the inhibition of Trp 2,3‐
dioxygenase.(46) Tryptophan is essential throughout pregnancy, first to meet the demand for protein 
synthesis during fetal development, to meet serotonin and kynurenine requirements, and to ultimately 
provide quinolinate for the production of NAD+, which plays a key role in mitochondrial function.(47) All of 
these requirements will increase with greater fetal growth, thereby leaving less free tryptophan for 
conversion into methoxykynurenate and indolelactic acid. Similar results were reported by Favretto et 
al.,(48) who observed higher levels of tryptophan and lower levels of kynurenine in cord blood of 
intrauterine growth‐restricted babies. Animal experiments have shown cord blood levels of tryptophan to 
be related to maternal plasma levels,(49) suggesting that cord blood levels may reflect tryptophan 
utilization earlier in pregnancy. Therefore, monitoring of tryptophan metabolism throughout pregnancy 
may have utility in tracking the health of the developing fetus. Similarly, lower levels of multiple 
acylcarnitine species (C4, C6, C8, C10, C12, C14, and C16) were associated with increased birth weight, 
likely reflecting differences in energy utilization during development. Carnitine is an essential factor in fatty 
acid metabolism, and its most important known metabolic function is to transport fatty acids into the 
mitochondria of cells for β‐oxidation.(50) The placenta has a high activity of fatty acid oxidation 
enzymes,(51) and where defects in long‐chain fatty acid oxidation are noted, there is a higher frequency of 
small‐for‐gestation‐age babies.(52) Walsh et al.(53) reported higher levels of acylcarnitines, including 
dodecanoylcarnitine identified in this study, in cord blood of infants asphyxiated during pregnancy, 
emphasizing their importance to healthy fetal development. Clemente et al.(54) recently demonstrated in 
the INMA and ENVIRONAGE cohorts that placental mitochondrial DNA content is associated with birth 
weight and may mediate the effects of environmental toxicants on birth weight. This supports our findings 
of the importance of metabolic pathways related to mitochondrial function. Mitochondria are particularly 
susceptible to oxidative stress and therefore may play a key role linking the fetal environment to growth. 
The ω‐3 fatty acid DHA has long been thought to be beneficial to fetal growth, and recent randomized 
control trials have found that taking DHA supplements by pregnant women was associated with increases 
in gestational length and birth weight.(55, 56) Here we observed a seemingly paradoxical negative 
association between cord blood DHA levels and birth weight. However, it has been reported that DHA 
intake by the mother explains only a small proportion of variance in DHA levels in cord blood,(57) with the 
rest presumably explained by endogenous processes. Reduced DHA levels in cord blood would result from 
increased utilization in central nervous tissues and from greater eicosanoid metabolism. We found DHA 
levels to be associated with a cluster of metabolites tentatively assigned as diacylglycerols, which are 
molecules required for the production of arachidonic acid, an ω‐6 fatty acid also involved in eicosanoid 
metabolism. Together these results highlight the role of long‐chain fatty acid and potentially eicosanoid 
metabolism in fetal growth. Eicosanoids, in particular, prostaglandins, are produced throughout pregnancy 
and play a role in regulating the maternal cardiovascular system and, like progesterone, are involved in 
signaling the onset of labor. Glycerophospholipids also showed significant disruption, indicating a variety of 
processes occurring in association with these molecular species. The lysoPCs were positively associated 
with birth weight and were negatively correlated with DHA and the diacylglycerols, suggesting some 
metabolic dependency. Positive associations between birth weight and lysoPCs have also been recently 
reported in a targeted analysis.(17) On the contrary, the PCs were associated with lower birth weight. This 
could reflect some cell membrane damage leading to the subsequent release of phospholipids, which have 
a variety of different proposed biological properties.(58) There is also recent evidence of antiphospholipid 
antibodies (and complement activation) cooperating in triggering a local inflammatory process,(59) which 
may be linked to suboptimal fetal development. 
We have complemented classical laboratory‐based metabolic feature annotation in this study with the use 
of the recently developed Mummichog algorithm to extract additional biological information at the 
pathway level. Because the method matches metabolic features to pathways based on annotation through 
exact mass only and does not account for any other physio‐chemical identifiers, results of these analyses 
should be interpreted with caution. However, because feature misidentification likely applies equally to 
both the numerator (significant features) and denominator (total features detected) in enrichment 
analyses, the impact of wrong annotation may be less dramatic at the pathway level. We found that the 
majority of pathways identified, including tryptophan metabolism, carnitine shuttle, glycerophospholipid 
metabolism, and C‐21 steroid hormone biosynthesis, were supported by the laboratory annotation of 
metabolites. 
Recent evidence indicates an effect of birth weight on later metabolic profile,(60) with similarities to 
profiles associated with weight status measured in later life stages, suggesting that the metabolic profile of 
an individual at the start of life may persist into later life, with implications for health throughout the life 
course. Therefore, one may speculate that metabolic pathways identified in this study may provide a link 
between the observed associations with between birth weight and disease in adult life. In particular, in 
utero levels of progesterone could plausibly mediate the observed association between high birth weight 
and later development of breast cancer,(6) as evidence is emerging that progesterone in adult life has a 
protective effect on breast cancer.(61) Conversely, tryptophan levels may play a role in the association 
between lower birth weight and increased risk of cardio‐metabolic disease in later life because tryptophan 
has been found to be predictive of subsequent development of type II diabetes in adult cohorts.(62) 
Following up current birth cohorts to adult life would be of great value to investigate these questions. 
The main limitation of this study was related to its use of cord blood. Because samples were by necessity 
collected at the time of delivery, the study was cross‐sectional in nature; therefore, it was difficult to 
disentangle whether perturbed metabolites were a cause or a result of variance in birth weight. However, 
cord blood provides a window into the direct supply of nutrients and other essential molecules to the 
developing fetus, and it also provides a snapshot of metabolism at the start of life. Our study was limited in 
scope to investigate changes specifically associated with low‐birth‐weight (<2500 g) babies because we 
sampled from across the general population of births. However, the generalizability of our results, also 
considering the large number of samples collected from birth cohorts from across Europe, is a strength. 
Although any single metabolomics method cannot cover all molecules of the cord blood metabolome, the 
UHPLC–MS platform we used represents a highly sensitive analytical technique able to measure hundreds 
to thousands of metabolites. Future work may include the incorporation of complementary metabolomics 
methods, other ‘omic approaches such as DNA methylation analysis and multiplex analysis of cytokines, 
which are of interest due to their role in mediating hormonal signaling and exploring the role of the cord 
blood metabolome in postnatal growth and development. 
Conclusions	
 
We have described metabolic profiles associated with birth weight among normal deliveries, highlighting 
the role of multiple metabolites in various pathways including tryptophan metabolism, fatty acid, and 
glycerophospholipid metabolism, and hormonal signaling. These results will have implications for antenatal 
and perinatal care, improving understanding of the pathways through which fetal growth may be affected, 
and may have implications for health in later life. 
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